13-HydroxylupanineCAS# 15358-48-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 15358-48-2 | SDF | Download SDF |
| PubChem ID | 73404 | Appearance | Powder |
| Formula | C15H24N2O2 | M.Wt | 264.4 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| SMILES | C1CC2C3CC(CN2C(=O)C1)C4CC(CCN4C3)O | ||
| Standard InChIKey | JVYKIBAJVKEZSQ-YHQUGGNUSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Targets | P450 (e.g. CYP17) |
13-Hydroxylupanine Dilution Calculator
13-Hydroxylupanine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.7821 mL | 18.9107 mL | 37.8215 mL | 75.643 mL | 94.5537 mL |
| 5 mM | 0.7564 mL | 3.7821 mL | 7.5643 mL | 15.1286 mL | 18.9107 mL |
| 10 mM | 0.3782 mL | 1.8911 mL | 3.7821 mL | 7.5643 mL | 9.4554 mL |
| 50 mM | 0.0756 mL | 0.3782 mL | 0.7564 mL | 1.5129 mL | 1.8911 mL |
| 100 mM | 0.0378 mL | 0.1891 mL | 0.3782 mL | 0.7564 mL | 0.9455 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- DL-Menthol
Catalog No.:BCN5950
CAS No.:15356-70-4
- D-Menthol
Catalog No.:BCN4973
CAS No.:15356-60-2
- Bexarotene
Catalog No.:BCC3737
CAS No.:153559-49-0
- [D-Trp34]-Neuropeptide Y
Catalog No.:BCC7690
CAS No.:153549-84-9
- Cevimeline hydrochloride hemihydrate
Catalog No.:BCC1471
CAS No.:153504-70-2
- Xanthinin
Catalog No.:BCN1686
CAS No.:153483-31-9
- Carbazeran citrate
Catalog No.:BCC6173
CAS No.:153473-94-0
- Desmethoxy yangonin
Catalog No.:BCN2295
CAS No.:15345-89-8
- Fexofenadine HCl
Catalog No.:BCC4542
CAS No.:153439-40-8
- WHI-P180 hydrochloride
Catalog No.:BCC4243
CAS No.:153437-55-9
- PD153035 hydrochloride
Catalog No.:BCC3617
CAS No.:153436-54-5
- AG-1478
Catalog No.:BCC3717
CAS No.:153436-53-4
- NS 1619
Catalog No.:BCC7779
CAS No.:153587-01-0
- GNE-9605
Catalog No.:BCC5458
CAS No.:1536200-31-3
- Dofequidar fumarate
Catalog No.:BCC4177
CAS No.:153653-30-6
- H-Ile-OEt.HCl
Catalog No.:BCC2961
CAS No.:15366-32-3
- 9,10-Bis(3,5-dihydroxyphenyl)anthracene
Catalog No.:BCC8793
CAS No.:153715-08-3
- Eriodictyol-8-glucoside
Catalog No.:BCN8029
CAS No.:153733-96-1
- Dioxopromethazine hydrochloride
Catalog No.:BCC8946
CAS No.:15374-15-9
- Fmoc-Trp-ol
Catalog No.:BCC2573
CAS No.:153815-60-2
- BLU9931
Catalog No.:BCC3979
CAS No.:1538604-68-0
- Boc-Gln-ONp
Catalog No.:BCC3383
CAS No.:15387-45-8
- NBOH-2C-CN hydrochloride
Catalog No.:BCC8025
CAS No.:1539266-32-4
- p-Hydroxyphenethyl vanillate
Catalog No.:BCN7555
CAS No.:1539303-03-1
Disposition of lupanine and 13-hydroxylupanine in man.[Pubmed:7810174]
Xenobiotica. 1994 Sep;24(9):933-41.
1. The in vivo disposition of lupanine and 13-Hydroxylupanine was studied in subjects identified as poor metabolizers (PM, n = 4) and extensive metabolizers (EM, n = 7) phenotypes for cytochrome P4502D6 (CYP2D6). 2. After oral administration (40.26 mumol), the half-life (t1/2) of lupanine determined from urinary excretion rate studies in EM subjects was 6.2 +/- 0.5 h (mean +/- SEM) with 95.5 +/- 6.0% of the dose recovered unchanged within 72 h. Similarly, in PM subjects t1/2 = 6.5 +/- 0.9 h and recovery 89.9 +/- 4.5%. 3. For orally administered 13-Hydroxylupanine (37.83 mumol) the t1/2 in EM subjects was 6.8 +/- 1.0 h with a recovery of 100.5 +/- 5.3%, and in PM subjects t1/2 = 5.9 +/- 1.6 h with a recovery of 102.5 +/- 4.8%. 4. The t1/2s of both lupanine and 13-Hydroxylupanine respectively did not differ significantly between EM and PM phenotypes. In addition, total recovery of dose for both alkaloids was similar between phenotypes. 5. In most subjects, > 76% of lupanine and > 85% of 13-Hydroxylupanine was recovered as the unchanged compound. Significant apparent partial dehydroxylation of 13-hydroxy-lupanine was observed in one EM (14% of dose) and one PM (34% of dose) subject. 6. Overall, the finding of a high urinary recovery of unchanged lupanine or 13-Hydroxylupanine together with similar t1/2s for both alkaloids in EM and PM CYP2D6 phenotypes suggests that clinical toxicity is unlikely to result from the use of lupin seed in footstuffs.
Accumulation of quinolizidine alkaloids in plants and cell suspension cultures: genera lupinus, cytisus, baptisia, genista, laburnum, and sophora.[Pubmed:17404991]
Planta Med. 1983 Aug;48(8):253-7.
The patterns of quinolizidine alkaloids in cell cultures of 10 species of Fabaceae were analyzed by high-resolution GLC and GLC-MS and compared with the alkaloids present in the leaves of the respective plants. Lupanine was produced in all 10 cell suspension cultures as the main alkaloid. It was accompanied by sparteine, tetrahydrorhombifoline, 17-oxosparteine, 13-Hydroxylupanine, 4-hydroxylupanine, 17-oxolupanine, and 13-Hydroxylupanine esters as minor alkaloids in some species. The alkaloid patterns of the plants differed markedly in that alpha-pyridone alkaloids were the major alkaloids in the genera Cytisus, Genista, Laburnum and Sophora but were not accumulated in the cell cultures. These data further support the assumption that the pathway leading to lupanine is the basic pathway of quinolizidine alkaloids biosynthesis and that the other alkaloids are derived from lupanine.
